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ABSTRACT
The burden of cancer continues to increase globally,
with substantial personal, societal, and economic con-
sequences. Population growth and aging underlie this
increase—a reflection of the effect of population health
interventions in the last two centuries. Much of this
gain has come through observation, derivation of evi-
dence, and rigorous application of valid science to the
public, both healthy and affected by diseases such as
cancer. Increasingly, molecular medicine will affect
the knowledge of cause and the personalization of
therapy. However, science informs the decision-mak-
ing process and places evidence within the beliefs of
individuals and society as they relate to innovation, judg-
ment, and values—the “logic” underlying alignment of
conventional and complementary (holistic) care as a
basis for compelling, consistent, and confident decisions.
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1. INTRODUCTION
Integrative medicine brings together the care philoso-
phies inherent in biomedicine—commonly conceived
as Western, “evidence-based,” and rooted in science—
and holistic medicine—often described in alternative
or complementary medicine terms and based strongly
in values or beliefs. Not uncommonly, this integration
is obscured by debate as to which paradigm is “right”
or “correct.” However, such a distinction is largely
without value if the goal is to justify “care and deci-
sion-making” according to science (biomedicine) or to
human values and beliefs (holistic medicine).
Science informs the process of decision-making
and human values place scientific evidence within the
context of the individual and society. In integrative care,
not only are practices based in science and complemen-
tary medicine brought together, also brought together are
the philosophies of analytic and deductive reasoning
based in evidence (science) and the contextualization
of science within the beliefs of individuals and society
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based on invention, judgment, and values (logic). A
satisfactory outcome for the person needing care is
confidence in the decision or decisions because infor-
mation was made available, because the processes of
assembling information were codified to allow for
alignment with beliefs, and because the rationale for
care formulated within the values of the individual was
such that the eventual decision is compelling and con-
sistent for that person.
2. DISCUSSION
2.1 Life, Death, and Human Values
In his treatise on the health of individuals and popula-
tions, Cairns notes that one cannot interpret health (life),
without first being knowledgeable about illness and
death 1. In Figure 1, attention is drawn to the unchang-
ing pattern of human mortality from the earliest of avail-
able evidence to the mid-19th century, preceding the
Industrial Revolution in the Westernized world. By
contrast, the profound change in mortality following
the Industrial Revolution (post-1850) is shown in the
population survival plot for England in the 1990s (Fig-
ure 1). The illustration demonstrates certain points:
• The power of interventions to change survival—in
this case, interventions largely related to the intro-
duction of public health measures and, to a lesser,
more recent degree, interventions based in medi-
cal treatment
• The value of observations validated through scien-
tific methods as a basis for improvements in sur-
vival
• The factual basis for interventions designed to
achieve longevity through informed, valid, applied
health policy
In large part, interventions designed to control com-
municable diseases (pathogen A causes disease B,
which can be controlled by intervention or interven-
tions C) have resulted in avoidance of premature death,
with resultant longevity. This benefit is based on a
proposition that values longevity.SUTCLIFFE
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Through observation, deductive reasoning, inter-
vention, validation through scientific method, analysis
of outcome, and application to practice through policy,
the population has, over one and one-half centuries,
gained on average an extra 30 years of life expectancy
from birth. However, in Westernized, high-income
economies, cancer and most chronic diseases causing
premature death are not communicable diseases for
which straightforward interventions are available. Ac-
cordingly, the value set for communicable disease (lon-
gevity through avoidance of premature death) is not
necessarily the same as that set for cancer or non-com-
municable diseases, in which functionality and quality
determinants may take greater precedence than does
longevity. Furthermore, the existing organization of
health services based on an acute reversible illness
model does not necessarily align well with the man-
agement of interventions to ameliorate the personal and
societal impacts of chronic disease.
In Figure 2, domains of scientific enquiry are re-
lated to effects on humanity according to the value
proposition applied to the preferred outcome. The il-
lustration draws recognition to the roles of individual
values and societal values in determining the expected
role of the intervention, thereby highlighting the di-
chotomy of the individual and society as consumer and
beneficiary and funder of health care in a publicly
funded health system.
2.2 The Cancer Control Problem
The population burden of cancer continues to increase,
primarily as a function of the increase in population
numbers and the structure of increasing age of our
society. Cancer is principally a disease of aging, the
rate increasing substantially after the age of 60 years.
The rising burden of cancer draws attention to sev-
eral issues:
• The effect of our interventions is insufficient to
offset the increasing incidence consequent upon
aging and population growth.
• The burden of cancer is not borne equally by indi-
viduals or populations: disparities exist within and
across communities and populations.
• The interpretation and the effect of the burden has
different meanings, all encompassed within the
context of health need. That is,
• “burden” as a statement of medically neces-
sary care,
• “burden” as a personal or societal consequence
of illness,
• “burden” as an expression of capacity to ben-
efit from intervention,
• “burden” as the capacity to afford necessary
health care, and
• “burden” as the expression of inequality to
achieve the gains of intervention.
The interpretation of burden has both a personal
and societal context and value proposition. Not-with-
standing the definition or value placed on burden, the
problem is not solely that the burden is rising—that is
a fact. The problem is what can be done about the ris-
ing burden, individually and societally. A further point
of importance is that the variation in health outcomes
across communities and populations has as much, if
not more, to do with variations in exposure to risk fac-
tors (environment, occupation, smoking, diet, obesity,
nutrition, and exercise, among others) as with varia-
tions in access to interventional care.
2.3 Cancer As a Process, Not an Event
Molecular medicine has identified cancer as a genetic
disease. Thus, the transformation of the healthy cell
through a series of events that lead to a cancer cell
with the properties of invasion and metastasis that may
lead to death is underwritten in serial and cumulative
changes within the genome of the cell. These are mea-
surable biologic changes that correlate with predispo-
sition, expression, sensitivity or resistance to therapies,
and the prognosis of cancer—a concept underlying
FIGURE 1 Patterns of survival in Breslau (17th century), Liverpool
(19th century), and modern England (late 20th century). From Cairns
1997 1, p. 21, reproduced with permission. FIGURE 2 Domains of scientific enquiry.INTEGRATING SCIENCE AND HUMAN VALUES
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aspects of the uniqueness of cancer to the individual
and to the personalization of care.
If we accept cancer as a process, arising in health
and, if unperturbed, resulting in illness, disability, and
death, then the strategy for cancer control must ad-
dress the process, not just the disease. In the case of
symptomatic cancer, the process is well advanced and
the opportunities for intervention limited to treatment
or palliation.
In the context of addressing the process of cancer,
the definition and the nature of interventions related to
cancer control assume importance 2. Cancer control
encompasses
• cancer treatment: treatment interventions for in-
dividuals with an established diagnosis of cancer,
commonly delivered through hospitals or cancer
centres, focused on the treatment episode and the
requirement for acute hospital-based services.
• cancer care: integrated programs across care set-
tings (hospital, community, home) by networks of
providers, with the goal of coordinated, continuous
services for the individual or individuals experi-
encing cancer and needing care.
• cancer control: interventions directed to the healthy
(at risk), those experiencing cancer, and those who
are cured (survivors) or dying of their cancer. The
interventions engage multiple sectors (health, edu-
cation, and transport, among others) and are ulti-
mately attempting to achieve a responsive,
efficient, effective, and sustainable system to im-
prove health and control cancer (as a process, not
as an event).
Within each of these contexts of cancer interven-
tion, values attached to the delivery of treatment, care,
or control will be relevant both from an individual and
a societal perspective. What ultimately drives the de-
cisions regarding provision and access to interventions?
How is this expressed from the perspective of the pub-
lic, the patient, the care provider, and the funder?
Factors of relevance relate to the quality of the ser-
vice (processes, outcomes), safety (incidents, errors,
adverse events), accessibility (distance, costs), avail-
ability (timeliness), cost-efficiency and cost-effective-
ness, satisfaction and sustainability (individually and
societally), and attachment of individual and societal
values and judgments to the foregoing parameters.
The premise underlying reductionism is that com-
plex problems can be solved by dividing them into
smaller—indeed individual—parts and by so doing,
represent the whole by the sum of the individual parts.
Scientific method would naturally lead us in the direc-
tion of the necessity to control all variation other than
the characteristics and performance related to a single
attribute or a small number of attributes. The current
pursuit of targeted therapies is an illustration of that
ideology, and it has been remarkably successful in a
number of circumstances—for example, imatinib and
tyrosine kinase inhibition in chronic myeloid leukemia
and gastrointestinal stromal tumours; rituximab for
CD20+ lymphoma; trastuzumab for breast cancer that
is positive for human epidermal growth factor recep-
tor. Yet notwithstanding these remarkable examples,
reductionism has profound limitations as a strategy to
explain and treat disease:
• It focuses on a single factor as cause.
• It emphasizes static control of function rather than
dynamic management of a range of function.
• It implies a one-target, one-risk-factor approach
to disease management.
• It takes a piecemeal approach to the multiple prob-
lems inherent in a chronic disease process.
Although inappropriately simplistic, reductionism
aligns more to the management of communicable dis-
ease (pathogen A causes disease B, necessitating inter-
vention C) than to the more complex gene–environment
interactions characterizing non-communicable diseases
including cancer.
Reductionism is a tool to investigate cause-and-
effect through the scientific method, but other than in
unique circumstances, it is incapable of addressing
the whole simply as the sum of the parts within a
system that is characterized by multiple biologic pro-
cesses, multiple genes within multiple pathways,
multiple targets, and multiple organ systems (tumour,
tissue micro-environment, organ, host, and host envi-
ronment). Even if a reductionist approach were to be
employed to “dissect” the multiple, individual path-
ways underlying the cause and expression of cancer,
would the establishment of therapeutic benefit through
current clinical trial methods be feasible or practi-
cal? Current oncologic practice would suggest that
only 5% of novel therapeutics actually enter clinical
application, with an expected investment in excess of
$800 million for each successful drug candidate
achieving approval 3.
Challenges within the reductionist approach have
stimulated the concept of a systems perspective to bi-
ology and health. In this construct, the holistic and com-
posite characteristics of the problem are recognized,
and the integration and interplay of relevant attributes
are explored as an explanatory basis for observations.
A relevant metaphor would be that “the forest cannot
be explained by the study of individual trees.” The
systems perspective would follow the principle that
behaviour is explained by the system as a whole, not
by the sum of the parts; that rarely is there a magic
bullet for a unique, single target that will address health
and illness; that many targets and many functions will
be relevant to the control of biologic networks that in-
clude both cancer cells and normal cells; that time,
space, and context will be relevant to how networks
behave and respond; and that health is better defined
by robustness, adaptability, and homeodynamism than
by normalcy, control, and homeostasis 4.SUTCLIFFE
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2.4 The Concept of Integrated Health
Accordingly, how might health be viewed from a sys-
tems perspective?
A definition that would align to this concept would
be “Health is the extent to which an individual or group
is able, on the one hand, to realize aspirations and sat-
isfy needs, and on the other hand, to change and cope
with the environment. Health is, therefore, seen as a
resource for everyday life, not the objective of living:
it is a positive concept emphasizing social and per-
sonal resources as well as physical capacities” (cited
in Young 1998 5).
This concept describes health in the context of
functional potential: the individual as an asset whose
function can be maximized and dysfunction minimized
through planned mitigating interventions, recognizing
that health risks (risk factors) are largely created and
maintained by social systems, that the magnitude of
risk exposure is a function of socio-economic dispari-
ties and psychosocial gradients, and that the develop-
ment of sustained health or illness plays out over
extended periods of time, crossing many stages of hu-
man development (prenatal to late adult, environmen-
tal, and socio-economic political domains) 6.
In this framework, disparities in health outcomes
and in psychological adjustment to varying health states,
rather than being attributable to discrete causes and
actions, are determined by cumulative, compounding
early-life events reflective of genes, biology, and envi-
ronment embedded within the individual’s make-up,
sustained by social, cultural, and economic forums, and
affected by biologic, psychosocial, socio-economic,
cultural, and physical environments. In each of these
contexts, evidence established through the scientific
method contributes to the development of a conceptual
model for health and illness and the resultant response
of health policies, practices, and systems 6.
3. CONCLUSIONS
Integrative care may be most aptly understood from
the perspective of the beneficiary of care, the patient,
rather than from the perspective of the care provider
(the biomedical, complementary, or alternative medi-
cine practitioner). In whose hands is the decision-mak-
ing process placed? Which tools and information
sources are made available to assist with the deci-
sion? How are the processes of reasoning codified—
be they scientific, evidence-based, or debated—to
provide a basis for decision-making that is aligned to
individual beliefs? And how are arguments for inter-
ventions placed within the values and the priorities of
the individuals?
Good decisions are made with the full confidence
of the patient. Confidence requires the information to
be sound, the rationale compelling, and the judgment to
be fully aligned to patient needs and values. The inputs
to the decision, be they scientific, holistic, complemen-
tary, or belief-based are all relevant inasmuch as trust
in the inputs will lead to trust in the decisions.
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